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OBJECTIVES: According to international guidelines on the management of asthma
(GINA), step down to the lowest dose of treatment that maintains control should be
considered for controlled patients. The aim of this analysis was to estimate the
costs and health outcomes associated with step down of controlled patients on
high dose fluticasone/salmeterol (FP/S 1000/100g daily) dry powder to either ex-
trafine beclometasone/formoterol (BDP/F 400/24g) pMDI or medium dose FP/S
(500/100g) dry powder in the UK setting. METHODS: A patient-level simulation
Markov model was defined to perform the simulation of a cohort of patients along
three comparative arms (FP/S 1000/100, FP/S 500/100, BDP/F 400/24). Transition
probabilities and healthcare resources costs were derived from patient-level data
of a recent multinational clinical trial comparing the three treatments. Direct costs
and health state utilities were sourced from published literature and UK current
prices and tariffs. The analysis was conducted from the UK National Healthcare
System perspective, over a six–month time horizon. Probabilistic sensitivity anal-
ysis was conducted. RESULTS: The analysis showed an ICER (Incremental Cost-
Effectiveness Ratio) of 57,300 GBP/QALY (Quality Adjusted Life Year) associated
with high dose FP/S 1000/100g versus extrafine BDP/F 400/24g and an ICER of
approximately 86,300 GBP/QALY associated with medium dose FP/S 500/100g ver-
sus BDP/F 400/24g. CONCLUSIONS: International guidelines recommend that
when asthma control is achieved and stabilized, treatment can be stepped down to
the lowest possible dose maintaining control. This analysis shows that maintain-
ing controlled patients on high dose FP/S is not a cost-effective strategy. Extrafine
BDP/F 400/24g daily can be considered to be a cost-effective option in the UK to
maintain control of asthmatic patients stepped down from high dose FP/S 1000/
100g daily.
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OBJECTIVES: In order to assess cost-effectiveness of SAL/FP Fen/IB versus Fen/IB
only in chronic obstructive pulmonary disease (COPD) treatment in different Rus-
sian regions we developed PHACTOR pharmacoeconomic model. METHODS: Our
model was based on the constant disease-specific data such as number of COPD
exacerbations and health care resource utilization data obtained from PHACTOR
(multicenter observational research of severe and very severe COPD). The method-
ology of PHACTOR research was published in 13th ISPOR Annual European Con-
gress (Research Abstract #PRS31). The following region-specific input data were
taken into account: drug prices (from the List of Vital and Essential Pharmaceuti-
cals), medical tariffs (from regional government regulations), gross domestic prod-
uct (GDP) per capita and average salary (from statistics service). SAL/FP  Fen/IB
was compared with Fen/IB only. ICERs (cost per COPD exacerbation avoided) were
calculated for all 83 Russian regions. Regional willingness to pay (WTP) was as-
sumed as three regional GDP per capita. RESULTS:Average yearly drug costs varied
from 29,539 RUR (Belgorod) to 35,264 RUR (Yakutia) for SAL/FP  Fen/IB treatment
and from 7,877 RUR (Altai Republic) to 9,442 RUR (Yakutia) for Fen/IB treatment.
Estimated yearly costs of COPD exacerbation treatment significantly varied from
6,552 RUR (Evreyskaya AO) to 63,053 RUR (Chukotka) for SAL/FP Fen/IB treatment
and from 12,592 RUR (Evreyskaya AO) to 109,019 RUR (Chukotka) for Fen/IB treat-
ment. SAL/FP  Fen/IB treatment was cost-saving (dominating) in 9 regions and
cost-effective in 74 regions (ICERWTP; in this regions ICERs were from 74 RUR to
4,605 RUR per COPD exacerbation avoided). CONCLUSIONS: This analysis demon-
strated that regional data had the biggest impact on final cost-effectiveness results.
In general case SAL/FP  Fen/IB treatment was cost-effective in most Russian
regions and cost-saving in some regions.
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OBJECTIVES: Daxas (roflumilast) is a new PDE4-inhibitor which targets the under-
lying inflammation in COPD. It is indicated for treating severe and very severe
COPD associated with chronic bronchitis and a history of frequent exacerbations.
The objective was to assess the incremental cost-effectiveness of using roflumilast
in a Swedish health care setting.The clinical trials for roflumilast have shown that
it consistently reduces exacerbations by approx. 20% and that it also provides a
lung function benefit of between 46-81 mL in addition to long-acting
bronchodilators. METHODS: A Markov model with a life time time horizon, one
month cycles and a discount rate of 3% was constructed using Treeage and an Excel
interface. The model uses comparator treatments relevant to Swedish guidelines
including long acting -2 agonist (LABA), inhaled corticosteroids (ICS) and long-
acting muscarinic antagonists(LAMA). All input parameters on costs and epidemi-
ology were from Swedish sources. Clinical effectiveness was based on results from
clinical trials along with indirect comparisons to address other comparators rele-
vant to the reimbursement authorities. The analysis had a societal perspective and
included lost productivity using a human capital approach. Outcomes were mea-
sured in QALYs. Uncertainty was addressed both through probabilistic sensitivity
analysis and one-way analyses of central variables. RESULTS: Treatment with ro-
flumilast (ROFL) as an add-on to LABA resulted in an incremental gain of 0.35 QALY.
From a societal perspective the ICER for LABAROFLU versus LABA was €18,000 per
QALY. The probability that LABAROFLU was cost-effective using a €50 000 threshold
was 97%. The ICER for LABAROFLU vs LABAICS was €14,500.
ROFLULAMALABAICS vs LAMALABAICS was €19,000. CONCLUSIONS: The
ICERs calculated were all well below commonly accepted willingness to pay for a
QALY in Sweden for all different comparator scenarios. The results were stable
when central variables were varied. Roflumilast is a cost-effective treatment for
severe and very severe COPD.
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OBJECTIVES: Chronic obstructive pulmonary disease (COPD) represents a consid-
erable burden on patients and health systems. Frequent exacerbations in patients
with COPD result in high healthcare costs. Roflumilast, an oral, selective phos-
phodiesterase-4 inhibitor, has been shown to reduce exacerbation rates and im-
prove lung function in patients with severe COPD. The objective of this analysis is
to estimate the long-term cost and outcomes of roflumilast added to several bron-
chodilator regimens in management of severe COPD from a health payer perspec-
tive in Switzerland. METHODS: A Markov cohort model was constructed to simu-
late the progression of disease, mortality, and exacerbation rates in patients with
COPD. Transition probabilities between severe and very severe COPD were deter-
mined from the published literature. Background mortality was expressed through
the risk of death in the general population and standardised mortality ratios (SMR);
hospital mortality was based on the published literature. A cost-effectiveness anal-
ysis was conducted for roflumilast as add-on treatment to LAMA, LABA/ICS and
LAMALABA/ICS, with the relative ratios of exacerbations rates derived from a
recently published multiple-treatment-comparison. Direct costs were sourced
from published Swiss data; utilities and disutilities of exacerbations were based on
published data. Analysis was conducted from the payer perspective in Switzerland,
for a lifetime horizon, with costs and outcomes discounted at 2.5% pa. A range of
sensitivity analyses were conducted. RESULTS: The added quality-adjusted life
years (QALY) and exacerbations avoided were: (0.275 and 2.56); (0.289 and 2.69); and
(0.278 and 2.59) for roflumilast added to LAMA, LABA/ICS, and LAMALABA/ICS
respectively. The incremental cost-effectiveness ratios (ICER) were CHF 18,512 per
QALY in LAMAroflumilast vs. LAMA, CHF 17,083 per QALY in LABA/ICSroflumilast
vs. LABA/ICS, and CHF 19,470 per QALY in LAMALABA/ICSroflumilast vs.
LAMALABA/ICS. CONCLUSIONS: For patients with severe COPD who continue to
exacerbate in clinical practice in Switzerland roflumilast can be a cost-effective
treatment option.
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OBJECTIVES: To evaluate cost-utility of fluticasone compared with beclometha-
sone and budesonide in COPD treatment in Poland. METHODS: A discreet event
simulation (DES) model was used to estimate utilities and costs of treatment (med-
icines, standard hospitalization, ambulatory visit cost for patients with COPD) on
fluticasone therapy in comparison to beclometasone and budesonide. Analysis
was performed from public payer’s perspective with a time horizon of 10 years.
Measures of medical effects of the therapies were obtained from a systematic
review of RCTs. The range of possible outcomes in the model included: exacerba-
tion, death, FEV1. Based on the systematic review fluticasone is more effective than
beclomethasone and budesonide in terms of FEV1 improvement. Differences in
costs and effects are presented per individual patient, described as statistically
significant (SS) or non-significant (NS) and discounted at 5% and 3.5% respectively.
Probabilistic sensitivity analysis was performed to estimate the probability that
fluticasone is cost-effective in Polish conditions (threshold about 105,000
PLN/QALY). RESULTS: The QALY difference between fluticasone and beclometha-
sone was 0.136 QALY (SS), and the cost difference was 4544 PLN (NS). In determin-
istic analysis incremental cost per QALY for fluticasone compared with beclome-
tasone was 33,333 PLN. The probability of fluticasone being cost-effective was
88.1%. The QALY difference between fluticasone and budesonide in 10 years per-
spective was 0.071 (NS). The cost difference was 9,027 PLN (SS). In deterministic
analysis incremental cost per QALY for fluticasone compared with budesonide was
127,190 PLN and exceeded the threshold. There was 44.9% chance that the flutica-
sone therapy was cost-effective in comparison with budesonide therapy.
CONCLUSIONS: Fluticasone therapy is more effective than beclomethasone (SS)
and budesonide (NS). It offers to patients with COPD an additional, pay-off thera-
peutic option.
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OBJECTIVES: To assess the relative effects and costs of Oralair® versus Grazax®,
ALK Depot SQ® (alongside symptomatic medication) and symptomatic treatment
alone for grass pollen allergic rhinitis; based on a systematic literature review,
meta-analysis and cost-effectiveness analysis. METHODS: The costs and effects of
three year treatment were assessed for a period of 9 years using a Markov model.
Efficacy was estimated using an indirect comparison of available clinical trials.
Estimates for immunotherapy discontinuation, occurrence of asthma, health state
utilities, drug acquisition costs, resource use and other medical costs were derived
from published sources. The analysis was conducted from the German payer’s
perspective, including Statutory Health Insurance (SHI) payments and co-pay-
ments by insurants. Effects were reported as quality adjusted life years (QALYs)
and symptom-free days (SFDs). The uncertainty around the incremental model
outcomes was tested by means of extensive deterministic univariate and probabi-
listic sensitivity analyses; various scenario analyses were also conducted.
RESULTS: In the base case analysis the model predicted a cost-utility ratio of Or-
alair® versus symptomatic treatment of €14,728 per QALY: incremental costs were
€1,356 (95%CI: €1,230;€1,484) and incremental QALYs 0.092 (95%CI: 0.052;0.140). Or-
alair® was the dominant strategy compared to Grazax® and ALK Depot SQ®, with
estimated incremental costs of -€1,142 (95%CI: -€1,255;-€1,038) and -€ 54 (95%CI:
-€188;€85) and incremental QALYs of 0.015 (95%CI: -0.025;0.056) and 0.027 (95%CI:
-0.022;0.075), respectively. At a willingness-to-pay threshold of €20,000, the proba-
bility of Oralair® being the most cost-effective treatment was predicted to be 79%.
The univariate sensitivity analyses show that the results were especially sensitive
to changes in transition probabilities of immunotherapy discontinuation and effi-
cacy estimates. Calculations on SFDs showed a comparable cost-effectiveness
trend. CONCLUSIONS: The analysis suggests Oralair® to be cost-effective com-
pared to Grazax®, ALK Depot SQ® and symptomatic treatment. The robustness of
these statements has been confirmed in extensive sensitivity analyses.
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OBJECTIVES: To conduct comparative pharmacoeconomic analysis of Methylpred-
nisolone aceponate (MA) and Betamethasone valerate (BV, brand name drug) for
treatment of atopic dermatitis and eczema in adults. METHODS: Review of the
published studies has been conducted to evaluate the comparative efficacy and
safety of studied drugs. The cost-minimization analysis was used further. The
pharmaceutical costs were calculated on the basis of average wholesale prices
(according to RMBC/IMS database for the 3d quarter of 2010) and average retail
prices in Moscow drugstores on 15.12.2010. The dosing regimen for both drugs was
1 g per 30 cm2 for 10 days, MA once a day, BV twice daily. RESULTS: A review of
clinical efficacy and safety of topical corticosteroids studies has not revealed sig-
nificant differences between MA and BV, though the experts consider MA to have
more favorable therapeutic index (combination of high anti-inflammatory activity
with reliable safety profile) compared to BV. With the retail price the costs of atopic
dermatitis and eczema treatment were almost equal for MA and brand name drug
of BV: MA cream - 257,85 19,83 RUB (9,15 0,70 $), BV cream - 265,61 33,34 RUB
(9,43 1,18 $), MA ointment- 257,85 19,83 RUB (9,15 0,70 $), BV ointment - 265,61
 33,34 RUB (9,43  1,18 $). CONCLUSIONS: Costs of MA and brand name BV for
treating atopic dermatitis and eczema in adults are identical in both retail and
wholesale market segments. Thus MA may be considered as a preferable option
being a medication with the better therapeutic index compared to BV.
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OBJECTIVES: The community-acquired respiratory tract infections (CARTI) are the
most frequent indicators for antibacterial preparations prescription, that requires
significant costs. Traditionally, penicillins and macrolids are used for it. Certain
perspectives of CARTI treatment are connected with the new generation respira-
tory fluoroquinolones use, that have high antibacterial activity in relation to S.
pneumoniae, but are rather expensive, especially in Ukraine. The aim of this work
was comparative evaluation of costs efficiency for patients treatment with com-
munity-acquired pneumonia (CAP) and exacerbations of chronic bronchitis (ECT)
with antibacterial preparations such as fluoroquinolone moxifloxacin versus ma-
crolid clarithromycin for the optimal use of patient’s or state’s financial expenses
grounding. METHODS: cost-minimization and sensitive analysis. RESULTS: The
results of G. Hoffken, H.P. Meyer, K. Sprenger et al.(1999) have been used for phar-
macoeconomic evaluation. In the trial 531 patients took place and it lasted 10 days.
The treatment regimes were: moxifloxacin (200 mg / day); moxifloxacin (400 mg /
day); clarithromycin (500 mg / two times a day). For pharmacoeconomic evaluation
of ECT treatment the results of trial (R. Wilson, R. Kubin, I. Ballin et al., 1999) have
been used: 649 patients took part in trial. The trial lasted 7 days. The treatment
regimes were: moxifloxacin (400 mg / one time a day) for 5 days, clarithromycin (500
mg / two times a day) for 7 days. Efficacy of moxifloxacin and clarithromycin for
CAP and ECT was equal. CONCLUSIONS: The results of “cost-minimization” anal-
ysis are sensitive to prices for drugs changing, and it does not create stable advan-
tages for clarithromycin. In case of maximal price for drugs, it is moxifloxacin that
has advantages.
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OBJECTIVES: Asthma is a common chronic disease affecting approximately 4 mil-
lion or 6.2% of Thais. Most asthmatic patients under the universal health coverage
(UC) scheme are poor, and cannot access to appropriate treatments due to geo-
graphical barriers, and high costs of medications. Severe asthmatic patients not
improved with inhaled corticosteroids (ICS) and long acting beta agonists (LABA)
rarely access to Omalizumab, an anti IgE medication, because of its high costs, and
exclusion from the UC benefit package. This study explores cost-utility analysis in
societal perspective between Omalizumab and standard medical treatments (ICS,
LABA, or oral corticosteroid) for severe asthmatic patients. METHODS: A mathe-
matical model using variables and data from comprehensive literature reviews and
asthma policy model were employed. Data on costs of medication and health ser-
vice use were computed from existing reports of the Ministry of Public Health. The
quality of life of asthma patients was assessed by the Asthma Quality of Life Ques-
tionnaire (AQLQ). RESULTS: Results from the mathematical model indicate that
using Omalizumab compared to other standard medical treatments would achieve
231 quality-adjusted years (QALY) with additional costs of 95 million Baht (approx-
imately US$ 3 million) for 100 severe asthmatic patients. The incremental cost-
effectiveness ratio (ICER) of Omalizumab is approximately 414,503 Baht (US$13,371)
per QALY gained. This ICER exceeds 1 GDP per capita which is the criteria for
including new health interventions into the UC benefit package. CONCLUSIONS:
Omalizumab is not cost-effective for severe asthma patients in Thailand. It is rec-
ommended that improving access to ICS and LABA and maintenance systemic
steroid should be the priority of medial care for asthma patients in Thailand, prior
to including Omalizumab into the UC benefit package. Omalizumab will be consid-
ered to be cost-effective if its cost decreases significantly and used for severe ast-
matic patients only.
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OBJECTIVES: Despite availability of current treatments, patients with chronic ob-
structive pulmonary disease (COPD), associated with chronic bronchitis, often ex-
perience life-threatening and costly exacerbations. The aim of this analysis was to
assess the long-term costs and outcomes associated with different treatment op-
tions for the management of severe COPD in the UK. METHODS: A Markov cohort
model was constructed to simulate decline from severe to very severe COPD (as
defined by the NICE/GOLD guidelines), treatment regimen changes, and death.
Community- and hospital-treated exacerbations were modelled as events within
each health-state. A fully incremental cost-effectiveness analysis was conducted
for LABA, LAMA, PDE-4 inhibitors, and ICS in various combinations. Transition
probabilities for COPD progression were derived from published epidemiological
sources. Relative rate ratios of exacerbations were taken from a recently published
mixed treatment comparison. Direct costs were sourced from UK data, and health
state utilities and exacerbation disutilities from the published literature. Analyses
were conducted from the UK NHS perspective, based on a 30-year time horizon,
with costs and outcomes discounted at 3.5% p.a. One-way and probabilistic sensi-
tivity analyses were conducted. RESULTS: The cost-efficiency frontier suggests
LAMA as the most effective monotherapy (£22,370, 5.421 QALYs). If patients con-
tinue to exacerbate, LAMALABA/ICS is a cost-effective second line option (£22,816,
5.484 QALYs, ICER £7,045/QALY), followed by LAMALABA/ICSroflumilast (£23,230,
5.509 QALYs, ICER £16,566/QALY). For patients who are intolerant to (or decline) ICS,
the addition of roflumilast to LAMALABA is a cost-effective treatment option (ICER
£13,764/QALY). The results were consistent under a variety of assumptions.
CONCLUSIONS: For severe COPD patients who continue to exacerbate, despite
current standard of care, the addition of roflumilast to the treatment regimen is
cost-effective in UK clinical practice. The addition of roflumilast in this manner is
consistent with the step-wise treatment paradigm recommended in NICE guide-
lines.
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OBJECTIVES: Chronic obstructive pulmonary disease (COPD) is a progressive (and
non-completely reversible) inflammatory lung disease. Disease progression is as-
sociated with increasing morbidity, mortality and economic burden. As compared
to usual care, tiotropium treatment and pulmonary rehabilitation programs have
been reported to improve the health of COPD patients in terms of exacerbations,
quality of life, and mortality. However, to date, the cost-effectiveness/utility of
these therapies in French settings have not been reported. We estimated the cost-
utility/effectiveness of these therapies in a patient population recruited from
French general practitioners and lung specialists. METHODS: A Markov model of
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